Up 60% In 2020, Here's Why DexCom Is Just Getting Started
More than 34 million Americans have diabetes and an additional 88 million are at risk of developing the disease, according to the American Diabetes Association. In this world of data, automation, and availability of information, it's hard to wrap your mind around the idea that roughly 10% of the U.S. population has diabetes and an additional 25% are at risk.
Diabetes is a chronic problem worldwide and there are many companies seeking to help diabetes patients. DexCom (NASDAQ: DXCM), a San Diego-based medical technology company is one that has been disrupting the industry. DexCom's continuous glucose monitoring (CGM) system allows diabetes patients to track their glucose levels via a wearable device that transmits biometrics to a smart device every five minutes. Its stock has risen more than 60% year to date, compared to the S&P 500's growth of nearly 15% over the same period. Over a five-year period, DexCom's stock has increased 344% compared to the broader market which rose 81%.
The question for investors heading into 2021 is whether the good times for DexCom will keep going and if it's a strong buy today.
Source Fool.com
